SCHEMBL24324813

SCHEMBL24324813

Cc1cc(NC(=O)C2COc3ccccc3O2)ccc1-c1cnco1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 10/20 0.67
RAB9A P51151 9/20 0.67
L3MBTL1 Q9Y468 4/20 0.58
MAPT P10636 5/20 0.57
ALDH1A1 P00352 4/20 0.57
MDM2 Q00987 1/20 0.57
HPGD P15428 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
CYP1A2 P05177 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
KDM4E B2RXH2 2/20 0.55
POLB P06746 2/20 0.55
PABPC1 P11940 1/20 0.55
APOBEC3A P31941 1/20 0.55
APOBEC3G Q9HC16 1/20 0.55
OPRM1 P35372 1/20 0.55
OPRD1 P41143 1/20 0.55
KMT2A Q03164 1/20 0.55
HSD17B10 Q99714 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22158344 0.88 MAPT (0.57) NPC1RAB9AL3MBTL1MAPTALDH1A1
SCHEMBL22158357 0.88 MAPT (0.57) NPC1RAB9AL3MBTL1MAPTALDH1A1
SCHEMBL22158313 0.88 IMPDH2 (0.62) NPC1RAB9AL3MBTL1KMT2A
SCHEMBL22170257 0.86 NFKB1 (0.55) NPC1RAB9AMAPTKMT2A
SCHEMBL1987143 0.83 ROCK2 (0.72) NPC1RAB9AL3MBTL1MAPTALDH1A1
SCHEMBL30292017 0.83 MAOB (0.68) POLBROCK2TP53
SCHEMBL30292044 0.83 MAOB (0.68) POLBROCK2TP53
SCHEMBL22165399 0.83 MAOB (0.68) POLBROCK2TP53
SCHEMBL24324206 0.80 NPC1 (0.63) NPC1RAB9AL3MBTL1HPGDSMN1; SMN2
SCHEMBL12561553 0.80 ROCK2 (0.73) NPC1RAB9AL3MBTL1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3902798-B1 N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES ENDOGENA THERAPEUTICS INC (US) 2023-12-20 EP disclosed
US-20220089583-A1 N-(4-(OXAZOL-5-YL)PHENYL) CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES ENDOGENA THERAPEUTICS, INC. (US) 2022-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089583-A1 N-(4-(OXAZOL-5-YL)PHENYL) CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES NR2E3, GFRA2, ALDH1A2 NPC1 4093/4885RAB9A 891/4885L3MBTL1 1828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.